HIV-1 replication is inhibited by a pseudo-substrate peptide that blocks Tat transactivation

Virology

Volumn 270, Issue 2, 2000, Pages 337-344

  Okamoto, Hiroshi ^a   Cujec, Thomas P ^b   Peterlin, B Matija ^b   Okamoto, Takashi ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CYCLIN DEPENDENT KINASE ACTIVATING KINASE; ELONGATION FACTOR; PHOSPHOTRANSFERASE; PROTEIN MC2P; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALIA; DNA VIRUSES; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0034630896     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0311     Document Type: Article

References (51)

1. Archambault J., Pan G., Dahmus G. K., Cartier M., Marshall N., Zhang S., Dahmus M. E., Greenblatt J. FCP1, the RAP74-interacting subunit of a human protein phosphatase that dephosphorylates the carboxyl-terminal domain of RNA polymerase IIO. J. Biol. Chem. 273:1998;27593-27601.
2. Benkirane M., Chun R. F., Xiao H., Ogryzko V. V., Howard B. H., Nakatani Y., Jeang K.-T. Activation of integrated provirus requires histone acetyltransferase. J. Biol. Chem. 273:1998;24898-24905.
3. Bieniasz P. D., Grdina T. A., Bogerd H. P., Cullen B. R. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J. 17:1998;7056-7065.
4. Bieniasz P. D., Grdina T. A., Bogerd H. P., Cullen B. R. Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription. Proc. Natl. Acad. Sci. USA. 96:1999;7791-7796.
5. Chun R. F., Jeang K. T. Requirements for RNA polymerase II carboxyl terminal domain for activated transcription of human retroviruses human T cell lymphotrophic virus I and HIV-1. J. Biol. Chem. 271:1996;27888-27894.
6. Cujec T., Okamoto H., Fujinaga K., Meyer J., Chamberlin J., Morgan D., Peterlin B. M. The HIV trans-activator Tat binds to the CDK-activating kinase (CAK) and activates the phosphorylation of the C-terminal domain of RNA polymerase II. Genes Dev. 11:1997a;2645-2657.
7. Cujec T. P., Cho H., Maldonado E., Meyer J., Reinberg D., Peterlin B. M. The human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzyme. Mol. Cell. Biol. 17:1997b;1817-1823.
8. Cullen B. R. Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism. Cell. 46:1986;973-982.
9. Cullen B. R. Does HIV-1 Tat induce a change in viral initiation right? Cell. 73:1993;417-420.
10. Dahmus M. E. Reversible phosphorylation of the C-terminal domain of RNA polymerase II. J. Biol. Chem. 271:1996;19009-19012.
11. Dignam J. D., Lebovitz R. M., Roeder R. G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11:1983;1475-1489.
12. Fisher R. P., Jin P., Chamberlin H. M., Morgan D. O. Alternative mechanisms of CAK assembly require an assembly factor or an activating kinase. Cell. 83:1995;47-57.
13. Fisher R. P., Morgan D. O. A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell. 78:1994;713-724.
14. Gallo R. C. Tat as one key to HIV-induced immune pathogenesis and Pat toxoid as an important component of a vaccine. Proc. Natl. Acad. Sci. USA. 96:1999;8324-8326.
15. Garber M. E., Wei P., KewalRamani V. N., Mayall T. P., Herrmann C. H., Rice A. P., Littman D. R., Jones K. A. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev. 12:1998;3512-3527.
16. Garcia-Martinez L. F., Ivanov D., Gaynor R. B. Association of Tat with purified HIV-1 and HIV-2 transcription preinitiation complexes. J. Biol. Chem. 272:1997b;6951-6958.
17. Garcia-Martinez L. F., Mavankal G., Neveu J., Lane W., Ivanov D., Gaynor R. Purification of a Tat-associatede kinase reveals a TFIIH complex that modulates HIV-1 transcription. EMBO J. 16:1997a;2836-2850.
18. Garriga J., Mayol X., Grana X. The CDC2-related kinase PITALRE is the catalytic subunit of active multimeric complexes. Biochem. J. 319:1996;293-298.
19. Goodrich J. A., Tjian R. Transcription factors IIE and IIH and ATP hydrolysis direct promoter clearance by RNA polymerase II. Cell. 77:1994;143-156.
20. Harlow E., Lane D. Antibodies: A Laboratory Manual. 1988;Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
21. Hayashi T., Ueno Y., Okamoto T. Identification of a new serine kinase that activates NF kappa B by direct phosphorylation. J. Biol. Chem. 268:1993;11380-11388.
22. Herrmann C. H., Rice A. P. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: Candidate for a Tat cofactor. J. Virol. 69:1995;1612-1620.
23. Hottiger M. O., Nabel G. J. Interaction of human immunodeficiency virus type 1 Tat with the transcriptional coactivators p300 and CREB binding protein. J. Virol. 72:1998;8252-8256.
24. Jones K. A. Taking a new TAK on Tat transactivation. Genes Dev. 11:1997;2593-2599.
25. Jones K. A., Peterlin B. M. Control of RNA initiation and elongation at the HIV-1 promoter. Annu. Rev. Biochem. 63:1994;717-743.
26. Kao S. Y., Calman A. F., Luciw P. A., Peterlin B. M. Anti-termination of transcription within the long terminal repeat of HIV-1 by Tat gene product. Nature. 330:1987;489-493.
27. Kashanchi F., Piras G., Radonovich M. F., Duvall J. F., Fattaey A., Chiang C. M., Roeder R. G., Brady J. N. Direct interaction of human TFIID with the HIV-1 transactivator tat. Nature. 367:1994;295-299.
28. Laspia M. F., Rice A. P., Mathews M. B. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell. 59:1989;283-292.
29. Makela T. P., Tassan J. P., Nigg E. A., Frutiger S., Hughes G. J., Weinberg R. A. A cyclin associated with the CDK-activating kinase MO15. Nature. 371:1994;254-257.
30. Mancebo H., Lee G., Flygare J., Tomassini J., Luu P., Zhu Y., Blau C., Hazuda D., Price D., Flores O. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev. 11:1997;2633-2644.
31. Marshall N., Dahmus G. K., Dahmus M. E. Regulation of carboxyl-terminal domain phosphatase by HIV-1 tat protein. J. Biol. Chem. 273:1998;31726-31730.
32. Mavankal G., Ignatius Ou S. H., Oliver H., Sigman D., Gaynor R. B. Human immunodeficiency virus type 1 and 2 Tat proteins specifically interact with RNA polymerase II. Proc. Natl. Acad. Sci. USA. 93:1996;2089-2063.
33. Nekhai S., Shukla R. R., Kumar A. A human primary T-lymphocyte-derived human immunodeficiency virus type 1 Tat-associated kinase phosphorylates the C-terminal domain of RNA polymerase II and induces CAK activity. J. Virol. 71:1997;7436-7441.
34. Neuman J. R., Morency C. A., Russian K. O. A novel rapid assay for chloramphenicol acetyltransferase gene expression. BioTechniques. 5:1987;444-447.
35. Okamoto H., Sheline C., Corden J., Jones K., Peterlin B. M. Trans-activation by human immunodeficiency virus Tat protein requires the C-terminal domain of RNA polymerase II. Proc. Natl. Acad. Sci. USA. 93:1996;11575-11579.
36. Okamoto T. Regulatory proteins of human immunodeficiency virus and therapy. Mohan O., Baba M. Anti-AIDS Drug Development; Challenges, Strategies and Prospects. 1995;117-127 Harwood Academic Publishers, Chur.
37. Okamoto T., Wong-Staal F. Demonstration of virus-specific transcriptional activator(s) in cells infected with HTLV-III by an in vitro cell-free system. Cell. 47:1986;29-36.
38. Parada C. A., Roeder R. G. Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain. Nature. 384:1996;375-378.
39. Patturajan M., Schulte R. J., Sefton B. M., Berezney R., Vincent M., Bensaude O., Warren S. L., Corden J. L. Growth-related changes in phosphorylation of yeast RNA polymerase II. J. Biol. Chem. 273:1997;4689-4694.
40. Peng J., Zhu Y., Milton J. T., Price D. H. Identification of multiple cyclin subunits of human P-TEFb. Genes Dev. 12:1998;755-762.
41. Poteet-Smith C. E., Shabb J. B., Francis S. H., Corbin J. D. Identification of critical determinants for autoinhibition in the pseudosubstrate region of type I alpha cAMP-dependent protein kinase. J. Biol. Chem. 272:1997;379-388.
42. Sato T., Asamitsu K., Yang J. P., Takahashi N., Tetsuka T., Yoneyama Y., Kanagawa A., Okamoto T. Inhibition of human immunodeficiency virus type 1 replication by a bioavailable serine/threonine kinase inhibitor fasudil hydrochloride. AIDS Res. Hum. Retroviruses. 14:1998;293-298.
43. Sorodski J. G., Rosen C., Wong-Staal F., Salahuddin S. K., Popovic M., Arya S., Gallo R. C., Haseltine W. A. Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat. Science. 227:1985;171-173.
44. Southgate C., Zapp M. L., Green M. R. Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein. Nature. 345:1990;640-642.
45. Wei P., Garber M. E., Fang S.-M., Fischer W. H., Jones K. A. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell. 92:1998;451-462.
46. West M. L., Corden J. L. Construction and analysis of yeast RNA polymerase II CTD deletion and substitution mutants. Genetics. 140:1995;1223-1233.
47. Yang X., Gold M. O., Tang D. N., Lewis D. E., Aguilar-Cordova E., Rice A. P., Herrmann C. H. TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of periferal blood lymphocytes and differentiation of promonocytic cell lines. Proc. Natl. Acad. Sci. USA. 94:1997;12331-12336.
48. Yang X., Herrmann C. H., Rice A. P. The human immunodeficiency virus Tat proteins specifically associate with TAK in vivo and require the carboxyl-terminal domain of RNA polymerase II for function. J. Virol. 70:1996;4576-4584.
49. Zhou Q., Chen D., Pierstorff E., Luo K. Transcription elongation factor P-TEFb mediates Tat activation of HIV-1 transcription at multiple stages. EMBO J. 17:1998;3681-3691.
50. Zhou Q., Sharp P. A. Tat-SF1: Cofactor for stimulation of transcriptional elongation by HIV-1 Tat. Science. 274:1996;605-610.
51. Zhu Y., Pe'ery T., Peng J., Ramanathan Y., Marshall N., Marshall T., Amendt B., Mathews M. B., Price D. H. Transcriptional elongation factor P-TEFb is required for HIV-1 Tat transactivation in vitro. Genes Dev. 11:1997;2622-2632.